My research informs healthcare decision-making through the application of economics, health economics, and decision theory. I started my academic career at the University of British Columbia, where I pursued cost and cost-effectiveness research using decision modeling. I moved to Scotland (University of Aberdeen, UK) to complete my PhD in health economics, focusing on preference-elicitation and cost-benefit analysis. I have previously held academic appointments at the University of Oxford (Dept. of Public Health and Somerville College) and University of Washington (Seattle, WA).
My PhD is in Health Economics (University of Aberdeen, UK). I also hold a Masters degree in Economics from Carleton University and a BA in Economics (High Hons) from the University of Saskatchewan.
SPPH 511 Cancer Control and Epidemiology (Winter 2015)
SPPH 581P Introduction to Health Economics (Fall 2015)
Selection of publications
- Regier DA, Bentley C, Mitton C, Bryan S, Burgess M, Chesney E, Coldman A, Gibson J, Hoch J, Rahman S, Sabharwal C, Sawka C, Schuckel V, Peacock S. Public Engagement in Priority-Setting: Results from a pan-Canadian Survey of Decision-Makers in Cancer Control. Social Science & Medicine; 2014: 122:130-139.
- Sung L, Regier DA. Decision making in pediatric oncology: evaluation and incorporation of patient and parent preferences. Pediatric Blood and Cancer 2013; 60(4); 558-563.
Preferences and value in health
- Regier DA, Peacock SJ, Pataky R,van der Hoek K, Jarvik G, Veenstra DA. Next generation genomic sequencing and the disclosure of incidental findings: a discrete choice experiment. In press, CMAJ
- Regier DA, Diorio C, Ethier MC, Alli A, Alexander S, Boydell KM, Gassas A, Taylor J, Kellow C, Mills D, Sung S. Discrete choice experiment to evaluate factors that influence preferences for antibiotic prophylaxis in pediatric oncology. PLoS1 2012; 7(10): e47470.
- Sung L, Alibibi SH, Ethier MC, Cheng S, Teuffel O, Fisman D, Regier DA. Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia. Journal of Clinical Epidemiology 2012; 65: 627-634.
- Regier DA, Friedman JM, Ryan M, Marra CA. Valuing the benefit of diagnostic testing of idiopathic mental retardation: willingness to pay from families of affected children. Clinical Genetics 2009; 75(6): 514-521.
- Bridges JFP, Hauber B, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. A checklist for the application of conjoint analysis in outcomes research: report of the patient preference methods-conjoint analysis work group. Value in Health 2011; 14: 403-413.
Econometrics and behavioral economics
- Regier DA, Watson V, Burnett H, Ungar W. Task complexity and response certainty in discrete choice experiments: an application to estimating preferences for drug treatments for juvenile idiopathic arthritis. Journal of Behavioral and Experimental Economics; 2014; 50: 40-49.
- Regier DA, Ryan M, Phimister E, Marra CA. Bayesian and classical estimation of mixed logit: an application to genetic testing. Journal of Health Economics 2009; 28(3): 403-413.
- Regier DA, Friedman JM, Marra CA. Value for money? Array genomic hybridization for diagnostic testing for genetic causes for intellectual disability. American Journal of Human Genetics 2010; 86(5): 765-772.
- Regier DA, Petrou S, Eddama O, Patel N, Henderson J, et al. The cost effectiveness of moderate hypothermia to treat neonatal encephalopathy: results from the TOBY trial. Value in Health 2010; 13(6): 695-702.
- Regier DA, Sunderji R, Llynd LD, Gin K, Marra CA. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation. Canadian Medical Association Journal 2006; 174(13): 1847-52.
My academic work operates within three methodological areas. The first explores theories of behavioral economics together with microeconometric techniques to produce individual-level estimates of personal utility using discrete choice experiments. In the context of personalized medicine, the second seeks to develop methods that integrate patient, physician, and general public utility values into an evaluation framework estimating the opportunity cost of making clinical decisions based on stratified or population-based evidence (called the expected value of individualized care). The final theme explores pursuing deliberative public engagement methods to inform healthcare priority setting.